An update on patent issues regarding antibody–drug conjugates: Patents
1. 文件大小不能超过300M, 允许上传文档或压缩包等
2. 请确保上传文献的真实性、完整性，不得对原文做任何修改
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
U Storz
nature biotechnology, 2026
nature.com
… A decade on, while the basic principles discussed in the first review of the patent
landscape of antibody–drug conjugates still apply, the ADC landscape has dramatically
evolved and diversified. … Patent-wise, following the basic formula antibody–linker–toxin,
each of the three elements can confer novelty and non-obviousness on an ADC-related
invention. In regard to reciting antibodies, linkers and toxins in a patent claim, different
levels of abstraction (Table 1) provide different options for protecting a final ADC product. Of …
